Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-17T13:10:00.472Z Has data issue: false hasContentIssue false
  • English
  • Français

Body cutaneous rash with olanzapine and risperidone: is there cross sensitivity?

Published online by Cambridge University Press:  04 February 2011

Vanessa Redmond
Vanessa Redmond*
Affiliation:
Specialist Mental Health Pharmacist, Central & North West London NHS Foundation Trust St Charles Hospital, UK
*
Correspondence to: Miss Vanessa Redmond, Central & North West London NHS Foundation Trust St Charles Hospital, London, W10 6DZ. Tel: 0208 206 7395; E-mail: vanessa.redmond@nhs.net
Get access

Abstract

Adverse cutaneous reactions are known to occur in approximately 5% of individuals prescribed antipsychotics. A case report of a 27 year old male who developed an allergic rash after six weeks of treatment with olanzapine, which reoccurred with more aggression following a single dose of risperidone, is described. To my knowledge, this is the first case to be reported in the literature.

Keywords

Rasholanzapinerisperidoneallergyerythema
Type
Case Report
Information
Journal of Psychiatric Intensive Care , Volume 7 , Issue 2 , December 2011 , pp. 115 - 118
Copyright
Copyright © NAPICU 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chae, B.J. and Kang, B.J. (2008) Rash desquamation associated with risperidone oral solution. Primary Care Companion to the Journal of Clinical Psychiatry. 10(5): 414–415.CrossRefGoogle ScholarPubMed
Desarkar, P. and Nizamie, S. (2006) Risperidone induced erythema multiforme minor. British Journal of Clinical Pharmacology. 62(4): 504–505.Google Scholar
Eli Lilly & Company Ltd. (2010) Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg coated tablets. Zyprexa velotab 5 mg, 10 mg, 15 mg and 20 mg orodispersible tablets. Summary of product characterstics, last updated 15/12/10. http://www.emc.medicines.org.ukGoogle Scholar
Janssen-Cilag Ltd. (2010) Risperdal tablets, liquid and quicklet. Summary of product characteristics, last updated 21/7/10. http://www.medicines.org.ukGoogle Scholar
Lundbeck Ltd. (2010) Clopixol tablets. Summary of product characteristics, last updated 26/4/10. http://www.medicines.org.ukGoogle Scholar
Marder, S., Essock, S.M., Miller, A.L., Buchanan, et al. (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry. 161: 1334–1349.CrossRefGoogle ScholarPubMed
Raz, A., Bergman, R., Eilam, O., Yungerman, T. and Hayek, T. (2001) A case report of olanzapine-induced hypersensitivity syndrome. American Journal of the Medical Sciences. 321(2): 156–158.CrossRefGoogle ScholarPubMed
Roche Products Ltd. (2008) Rivotril Tablets. Summary of product characteristics, last updated 20/10/08. http://www.medicines.org.ukGoogle Scholar
Warnock, J.K. and Morries, D.W. (2002) Adverse cutaneous reactions to antipsychotics. American Journal of Clinical Dermatology. 3(9): 629–636.CrossRefGoogle ScholarPubMed